AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 377
- Registration Number
- NCT00359879
- Locations
- 🇲🇽
Research Site, San Luis Potosi, Mexico
Exenatide Versus Glimepiride in Patients With Type 2 Diabetes
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1029
- Registration Number
- NCT00359762
- Locations
- 🇬🇧
Research Site, Wiltshire, United Kingdom
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Aclidinium bromideDrug: Placebo
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 804
- Registration Number
- NCT00358436
- Locations
- 🇺🇸
Almirall Investigational Sites#930, Los Angeles, California, United States
🇺🇸Almirall Investigational Sites#922, Los Angeles, California, United States
🇺🇸Almirall Investigational Sites#902, Riverside, California, United States
Ropivacaine Versus Bupivacaine for Spinal Anaesthesia in Patients Undergoing Unilateral Lower Limb Surgery
- Conditions
- Anesthesia,Spinal
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 220
- Registration Number
- NCT00358280
- Locations
- 🇨🇳
Research Site, Xi'an, China
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2010-12-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT00357110
- Locations
- 🇳🇴
Research SIte, Porsgrunn, Norway
🇳🇴Research Site, Trondheim, Norway
A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 163
- Registration Number
- NCT00357370
- Locations
- 🇺🇸
Nea Clinic, Jonesboro, Arkansas, United States
🇺🇸Mountain Diabetes And Endocrine Center, Asheville, North Carolina, United States
🇺🇸Research Institute Of Dallas, P.A., Dallas, Texas, United States
Iressa Follow-up Trial
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT00357734
- Locations
- 🇩🇪
Research Site, Tübingen, Germany
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
- First Posted Date
- 2006-07-24
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 173
- Registration Number
- NCT00355615
- Locations
- 🇪🇸
Research Site, Reus, Spain
🇳🇱Research SIte, Waalwijk, Netherlands
An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
- Conditions
- Barrett's Esophagus
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00352261
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States
🇺🇸Research SIte, Springfield, Missouri, United States
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 494
- Registration Number
- NCT00351910
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden